Medtronic Treat to Range (TTR) Closed-Loop Control
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate a treat-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes.
| Condition | Intervention |
|---|---|
|
Diabetes Mellitus Type 1 Diabetes Metabolic and Nutritional Disorders |
Device: TTR controller (Medtronic) |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Medtronic Treat to Range (TTR) Closed-Loop Control: Tuning a Treat-to-Range Controller for the Effects of High and Low Glycemic Index Meals |
- Safety and efficacy [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]Outcome Measure: 75% of admissions successful with our nominal tuning parameters, and for all subjects to be successful in meeting our safety criteria with no more than 2 adjustments of algorithm tuning parameters.
| Estimated Enrollment: | 24 |
| Study Start Date: | December 2011 |
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: TTR controller
Treatment with treat-to-range closed-loop controller
|
Device: TTR controller (Medtronic)
Subjects will arrive in the morning, the controller will be initialized, and then they will give their usual premeal insulin bolus for breakfast. At lunch, they will either have a low glycemic index meal or a high glycemic index meal and the meal bolus will be omitted. The device will be turned off before dinner, they will have their usual insulin bolus for dinner, eat dinner, and then be discharged to home. On another admission, they will receive an insulin dose before lunch which will be 120% of their usual insulin bolus.
|
Detailed Description:
The purpose of this study is to demonstrate the safety and efficacy of a closed-loop "treat-to-range" (TTR) system in an inpatient clinical research center setting. The TTR system only effects insulin delivery when the glucose is projected to be above or below specified target ranges. These initial studies will assess the safety of this algorithm (mathematical equation) under the extreme conditions of a missed meal insulin bolus and meal over-insulinization. This is a "hybrid" system, which allows the research team to deliver insulin boluses manually with the TTR controller only becoming active when blood glucose levels are projected to be out of the specified range.
Eligibility| Ages Eligible for Study: | 15 Years to 30 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year.
- Age 15 years to less than 30 years old.
- HbA1c < 10%.
- Subject has used a downloadable insulin pump for at least 3 months.
- Parent/guardian and subject understand the study protocol and agree to comply with it.
- Subject comprehends written English.
- Subject has a home computer with email access.
- For females, subject not intending to become pregnant during the study.
- No expectation that subject will be moving out of the area of the clinical center during the study.
- Informed Consent Form signed by the subject or guardian.
- Subjects cannot have had a severe hypoglycemic event described as a seizure, loss of consciousness requiring an emergency department visit or hospitalization within 6 months of enrollment.
Exclusion Criteria:
- Asthma if treated with systemic or inhaled corticosteroids in the last 6 months; Subject has taken oral or injectable corticosteroids within the last 30 days; Current use of oral/inhaled Glucocorticoids
- Cystic fibrosis
- Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian)
- Use of non-insulin medications that may affect blood glucose (eg Symlin),
- Systolic blood pressure >140 on screening; Diastolic blood pressure >90 on screening
- History of seizure or loss of consciousness in the last 6 months.
- Adhesive allergies; Active skin condition that would affect sensor placement
- History of heart disease
- Active Graves disease;
- Currently on beta blocker medication;
- Unwilling or unable to follow the protocol;
- History of diagnosed medical eating disorder;
- History of known illicit drug abuse or prescription drug abuse;
- History of current alcohol abuse;
- History of visual impairment which would not allow subject to participate
- Currently participating in an investigational study (drug or device);
- Other major illness that in the judgment of the investigator might interfere with the completion of the protocol: Adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment
Contacts and Locations| Contact: Kari Benassi, RN, FNP | 650-736-8948 | karis@stanford.edu |
| Contact: Satya Shanmugham, BS | 650-736-8142 | satyas1@stanford.edu |
| United States, California | |
| Stanford University and Stanford Hospital & Clinics | Recruiting |
| Stanford, California, United States, 94305 | |
| Contact: Kari Benassi, RN, FNP 650-736-8948 karis@stanford.edu | |
| Principal Investigator: | Bruce Buckingham, MD | Stanford University |
More Information
No publications provided
| Responsible Party: | Bruce A. Buckingham, Director, Pediatric Endocrinology, Stanford University |
| ClinicalTrials.gov Identifier: | NCT01490151 History of Changes |
| Other Study ID Numbers: | G110143, SPO 53117 |
| Study First Received: | December 8, 2011 |
| Last Updated: | December 9, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Stanford University:
|
Hormone Diabetes Mellitus |
Type 1 Immune Metabolic disorder |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 1 Nutrition Disorders Glucose Metabolism Disorders |
Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases |
ClinicalTrials.gov processed this record on June 18, 2013